Research Peptide
Tirzepatide
An FDA-approved dual hormone receptor agonist (GLP-1 and GIP) marketed as Mounjaro (type 2 diabetes) and Zepbound (chronic weight management). Mimics two natural gut hormones to suppress appetite, slow gastric emptying, and promote fullness (GLP-1), while enhancing insulin secretion, improving fat metabolism, and supporting better blood sugar control (GIP). This dual action leads to significant reductions in calorie intake, body weight (primarily fat mass), and blood glucose levels.
Overview
Tirzepatide (LY3298176) is a synthetic dual-agonist peptide that activates both the GLP-1 receptor (glucagon-like peptide-1) and the GIP receptor (glucose-dependent insulinotropic polypeptide). It represents a mechanistic advance over single-agonist GLP-1 compounds, simultaneously harnessing both incretin hormone pathways to produce complementary effects on insulin secretion, appetite regulation, and gastric motility.
Structurally, tirzepatide is engineered as a GIP analogue with modifications enabling GLP-1R co-activation, resulting in a molecule with distinct pharmacodynamic properties compared to either pathway activated alone. Its dual mechanism is hypothesized to produce synergistic improvements in glycemic control and weight-related metabolic parameters.
Research Highlights
Phase 3 randomized controlled trials demonstrated approximately 20% average body weight reduction in participants treated with tirzepatide, alongside significant improvements in HbA1c levels and fasting glucose. The SURPASS trial program documented outcomes superior to semaglutide monotherapy in head-to-head comparisons across multiple metabolic endpoints.
Mechanistically, tirzepatide stimulates pancreatic insulin release in a glucose-dependent manner, slows gastric emptying to extend satiety signals, and reduces appetitive drive through central GLP-1 receptor engagement. Researchers continue to investigate its effects on liver fat content, cardiovascular risk factors, and the relative contributions of GIP versus GLP-1 receptor activation to its overall metabolic profile.
For research use only. Not intended for human consumption.
Specifications
| Molecular Weight | 4,813 g/mol |
| Chemical Formula | C₂₂₅H₃₄₈N₄₈O₆₈ |
| CAS Number | 2023788-19-2 |
| PubChem CID | 163285897 |
| Synonyms | LY3298176, LY-3298176, Mounjaro (clinical name) |
| Purity | ≥99% (HPLC verified) |
| Form | Lyophilized powder |
| Storage | −20°C. Stable ≥24 months lyophilized. |
| Origin | USA |
Certificate of Analysis
Each batch is independently tested by a third-party laboratory. A Certificate of Analysis (COA) confirming purity and identity is available upon request. Contact us with your order number to receive the COA for your specific lot.